Jul. 13, 2011

Health Canada and European Medicines Agency Approves BENLYSTA™

July 13, 2011

Health Canada and European Regulators have approved BENLYSTA™ (belimumab), a new drug specific for the treatment of systemic lupus erythematosus. The announcement was made today by GlaxoSmithKline Inc. (GSK) and Human Genome Sciences (HGS) who are developing BENLYSTA™ under a co-development and co-commercialization agreement entered into in 2006. BENLYSTA™ is expected to become available to patients in Canada in September of this year. 

Read more about BENLYSTA™ in Canada.


Related Stories

General News | Oct. 31, 2011

Lupus Organizations Around the Globe Urge NICE to Provide Coverage for Benlysta®

National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.

General News | May. 20, 2011

European Review Board Issues Positive Opinion for Benlysta®

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA®.